[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100139203":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":7,"locations":13,"responsibleParty":25,"collaborators":27,"id":29,"slug":30,"hasResults":31,"nctId":32,"briefTitle":33,"officialTitle":34,"acronym":7,"eligibilityCriteria":35,"healthyVolunteers":31,"sex":36,"minAge":37,"maxAge":7,"enrollmentInfo":38,"targetDuration":7,"studyType":41,"phases":7,"briefSummary":42,"conditions":43,"keywords":45,"overallStatus":49,"whyStopped":7,"lastUpdateSubmitDate":50,"lastUpdatePostDateStruct":51,"startDateStruct":54,"completionDateStruct":56,"leadSponsor":58,"locationsCount":59},{"fullName":5,"class":6},"Merck KGaA, Darmstadt, Germany","INDUSTRY",null,[9],{"name":10,"affiliation":11,"role":12},"Medical Director","Merck Quimica Argentina S.A.I.C","STUDY_DIRECTOR",[14],{"facility":15,"status":7,"city":16,"state":7,"zip":7,"country":17,"countryCode":18,"cosmosGeoPoint":19,"geoPoint":24,"contacts":7},"Htal Vicente Lopez","Vicente López","Argentina","AR",{"type":20,"coordinates":21},"Point",[22,23],-58.4737,-34.52947,{"lat":23,"lon":22},{"type":26,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR",[28],{"name":11,"class":6},"100139203","prevalence-of-the-mutational-status-of-v-ki-ras2-kirsten-rat-sarcoma-viral-oncogene-homolog-kras-in-metastatic-colorectal-cancer-mcrc-in-argentine-patients-100139203",false,"NCT01082757","Prevalence of the Mutational Status of V-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) in Metastatic Colorectal Cancer (mCRC) in Argentine Patients","Prevalence of the Mutational Status of KRAS in mCRC in Argentine Patients","Inclusion Criteria:\n\n* Subjects who have signed written informed consent before any study-related procedure\n* Subjects with histologically confirmed adenocarcinoma of the colon\u002F rectum, T1-4 N0-2 M1 or rT1-4 N0-2 M1\n* Subjects with age above 21 years\n* Subjects willing to provide information required by protocol\n* No previous systemic treatment for mCRC\n\nExclusion Criteria:\n\n* Subjects with known pregnancy\n* Subjects with previous systemic therapy for mCRC\n* Subjects with active infection or any other serious condition which, in the investigator´s mind, may render the subject ineligible for the study\n* Subjects with medical or psychological condition, which, in the opinion of the investigator, would not permit the subject to sign meaningful informed consent","ALL","22 Years",{"count":39,"type":40},1524,"ACTUAL","OBSERVATIONAL","This observational, prospective, multicentric study is being conducted to record the prevalence of KRAS mutations in the Argentine mCRC population.",[44],"Colorectal Neoplasms",[46,47,48],"Colorectal neoplasms","metastasis","colorectal cancer","COMPLETED","2014-07-30",{"date":52,"type":53},"2014-07-31","ESTIMATED",{"date":55,"type":7},"2009-06",{"date":57,"type":40},"2013-08",{"name":5,"class":6},1]